Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter Phase III Randomized Study With Second Line Chemotherapy Plus or Minus Bevacizumab in Patients With Platinum Sensitive Epithelial Ovarian Cancer Recurrence After a Bevacizumab/Chemotherapy First Line

NCT01802749 is registered in ClinicalTrials.gov with National Cancer Institute, Naples as lead sponsor.

NCT NCT01802749
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01802749 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter Phase III Randomized Study With Second Line Chemotherapy Plus or Minus Bevacizumab in Patients With Platinum Sensitive Epithelial Ovarian Cancer Recurrence After a Bevacizumab/Chemotherapy First Line
Lead sponsor
National Cancer Institute, Naples
Phase
Phase 3
Overall status
Unknown status
Start date
November 30, 2013
Completion date
December 31, 2023
Enrollment
406 (actual)
Sites
82

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent ovarian cancer